The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy Results from an Open-Label, Randomized Phase II Clinical Trial
JOURNAL OF THORACIC ONCOLOGY. Bd. 5. H. 7. 2010 S. 1060-1067
Erscheinungsjahr: 2010
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Sebastian, M (Autor)
Reck, M (Autor)
Waller, CF (Autor)
Kortsik, C (Autor)
Frickhofen, N (Autor)
Schuler, M (Autor)
Fritsch, H (Autor)
Gaschler-Markefski, B (Autor)
Hanft, G (Autor)
Munzert, G (Autor)
von Pawel, J (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
